Business Context and Reporting Period
Company: Sanara Medtech Inc. (SMTI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2026
Reporting Period: Event date June 2, 2026; Signed June 4, 2026
The filing reports the termination of a material definitive agreement in connection with a strategic shift to focus on soft tissue repair and bone fusion products for the surgical market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a specific corporate event rather than a periodic financial report.
Material Changes
- Termination of Services Agreement: The Company terminated the Transaction Advisory Services Agreement entered into on March 20, 2023, with The Catalyst Group, Inc. ("Catalyst").
- Effective Date: The termination is effective immediately as of June 2, 2026.
- Financial Impact: The Company did not pay a fee or penalty in connection with the termination.
- Related Party Context: Catalyst is founded and managed by the Company's Chairman, Ronald T. Nixon, and its affiliates beneficially own more than 5% of the Company's outstanding common stock.
Outlook, Risks, and Management Commentary
Strategic Shift: Management is pivoting strategy to concentrate on soft tissue repair and bone fusion products for the surgical market.
Remaining Obligations: Certain covenants from the terminated agreement, specifically those relating to indemnification and confidentiality, remain in full force and effect.
Risks and Contingencies: The filing does not disclose new risks or contingencies beyond the standard implications of terminating a related-party advisory agreement.
Investor Verification Checklist
- Verify the specific details of the new strategic focus on soft tissue repair and bone fusion products.
- Confirm the extent of Ronald T. Nixon's and Catalyst's remaining beneficial ownership in the Company.
- Review the specific indemnification and confidentiality covenants that remain active post-termination.
- Check for any subsequent filings regarding the Company's operational progress under the new strategy.